Hemcheck Sweden AB has been selected by a jury to participate in the EIT Health Bridgehead Europe program. The EIT, European Institute for Innovation and Technology, is set up by the European Union to strengthen Europe´s innovation capacity. EIT Health, which is part of EIT, is the world’s largest innovation network and consists of over 140 partners from business, research institutes, and universities in Europe.
Bridgehead Europe is a program where participants are allocated EUR 30,000 in funds to be used for one year to finance internationalization activities in selected markets in the EU, where the participating company does not have its principal place of residence.
– Being selected as participants shows that important decision-makers in other countries see our solutions as interesting and that there is good market potential in other European countries. It will strengthen our opportunities in the selected countries and hopefully accelerate the pace of commercialization, which is very positive, says Joen Averstad, CEO Hemcheck.
The program will begin at the end of June to finally select the markets that Hemcheck will focus on under the program, such as German-speaking countries, France, Benelux, or Spain, and to select local partners for the relevant markets that will support the work.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About EIT and Bridgehead Europe at:
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes, and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on Juni 1, 2020 at 10.00